EXECUTIVE SUMMARY



First Half 2024


Main figures €Mn


Op. Revenue	EBITDA	EBIT
329.3 (-14%)	69.9 (-28%)	56.5 (-34%)
Net profit	Capex	Net debt
44.3 (-33%)	18.7 (+3%)	74.7

2024 operating revenue guidance: Decrease by a mid-single-digit percentage vs 2023

- ✓ ROVI forecasts potential Risperidone ISM® sales of between 200 and 300 million euros globally in upcoming years
- ✓ Completion of the Buy-Back Programme launched on 26 July 2023
- ✓ ROVI signs an agreement to manufacture pre-filled syringes for a global pharmaceutical company


Operating revenue €Mn






⁽¹⁾Contract Development and Manufacturing Organisation

To obtain further information on the altermative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the first half of 2024. Said document is available on ROVI's website and may be accessed on the following link <u>https://www.rovi.es/es/es/shareholders-investors/financial-business-information</u>



To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRss, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the first half of 2024. Said document is available on ROVI's website and may be accessed on the following link <u>https://www.rovi.es/en/shareholdersinvestors/financial-business-information</u>

EBITDA €Mn



(1) Calculated excluding R&D expenses in H1 2024 and H1 2023

News flow

<u>SPECIALTY</u> <u>PHARMA</u>

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
 ✓ Granting by the
- competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Evolution of Moderna's vaccine manufacturing
- ✓ Announcement of new contracts

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe, Canada, Australia and other countrios
- ✓ Marketing of
- ✓ Phase I clinical development of a three-monthly formulation of lotrozola (Lotrozola)
- letrozole (Letrozole LEBE) ✓ Phase I clinical
- development of Risperidone for a 3monthly injection